Optimizing the "Drug-Like" Properties of Leads in Drug Discovery
| Autor Corporativo: | |
|---|---|
| Otros Autores: | , , , , |
| Formato: | eBook |
| Lenguaje: | English |
| Publicado: |
New York, NY :
Springer New York : Imprint: Springer,
2006.
|
| Edición: | 1st ed. 2006. |
| Colección: | Biotechnology: Pharmaceutical Aspects ;
IV |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1007/978-0-387-44961-6 |
Tabla de Contenidos:
- Strategic Use of Preclinical Pharmacokinetic Studies and In Vitro Models in Optimizing ADME Properties of Lead Compounds
- Role of Mechanistic Transport Studies in Lead Optimization
- Metabolic Activation-Role in Toxicity and Idiosyncratic Reactions
- Case History — Use of ADME Studies for Optimization of Drug Candidates
- Solubility, Solubilization and Dissolution in Drug Delivery During Lead Optimization
- Lipid-based Systems, Drug Exposure and Lead Optimization
- Biopharmaceutics Modeling and the Role of Dose and Formulation on Oral Exposure
- Application of Physicochemical Data to Support Lead Optimization by Discovery Teams
- Computational Models Supporting Lead Optimization in Drug Discovery
- Prodrug Strategies for Improving Drug-Like Properties
- The Application of Multivariate Data Analysis to Compound Property Optimization
- Case History: Toxicology Biomarker Development Using Toxicogenomics
- Predicting Idiosyncratic Drug Reactions
- Elementary Predictive Toxicology for Advanced Applications
- The Application of PK/PD Modeling and Simulations During Lead Optimization
- Early Preclinical Evaluation of Brain Exposure in Support of Hit Identification and Lead Optimization
- Optimizing Biomarker Development for Clinical Studies at the Lead Optimization Stage of Drug Development
- The Relevance of Transporters in Determining Drug Disposition.